<DOC>
	<DOCNO>NCT00004857</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody alemtuzumab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness fludarabine follow alemtuzumab treating patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine Followed Alemtuzumab Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall response rate previously untreated patient stage I , II , III , IV B-cell chronic lymphocytic leukemia treat fludarabine induction follow alemtuzumab consolidation . II . Determine infectious toxic effect feasibility regimen patient population . III . Determine treatment-related toxic effect , include infection injection site reaction , subcutaneous v intravenous alemtuzumab patient treat regimen . IV . Determine progression-free overall survival patient treat regimen . V. Determine immunologic effect regimen patient . OUTLINE : Patients receive fludarabine IV 30 minute 5 day week . Treatment repeat every 28 day 4 course absence disease progression . Patients undergo clinical stag completion course 4 fludarabine follow 2 month observation . Patients stable respond disease receive alemtuzumab subcutaneously 3 day week 6 week . Patients undergo clinical stag completion 6 week alemtuzumab follow 2 month observation . Patients follow every 3 month 1 year every 6 month 8 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Specific Diagnosis BCell CLL 1.1 An absolute lymphocytosis &gt; 5,000/µl 1.1.1 Morphologically , lymphocytes must appear mature &lt; 55 % prolymphocytes . 1.1.2 Bone marrow examination must include least unilateral aspirate biopsy . The aspirate smear must show &gt; 30 % nucleated cell lymphoid bone marrow core biopsy must show lymphoid infiltrates compatible marrow involvement CLL . The overall cellularity must normocellular hypercellular . 1.1.3 Local institution lymphocyte phenotype must reveal predominant Bcell monoclonal population share Bcell marker ( CD19 , CD20 , CD23 , CD24 ) CD5 antigen , absence panTcell marker . Additionally , Bcells must monoclonal regard expression either κ λ surface immunoglobulin expression low density . Patients bright surface immunoglobulin level must CD23 coexpression . 1.2 Staging 1.2.1 Patients must intermediate highrisk category modify threestage Rai staging system ( i.e. , stage I , II , III , IV ) per protocol . 1.2.2 Patients intermediaterisk group must evidence active disease demonstrate least one follow criterion : Massive progressive splenomegaly and/or lymphadenopathy Presence weight loss &gt; 10 % precede 6 month period ; Grade 2 3 fatigue Fevers &gt; 100.5°C night sweat great 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2 month period anticipate doubling time le 6 month . 2 . Prior Treatment : No prior therapy CLL include corticosteroid autoimmune complication develop since initial diagnosis CLL . 3 . No medical condition require chronic use oral corticosteroid . 4 . Age ≥18 year . 5 . Performance Status 0 2 . 6 . No HIV disease . Due alteration host immunity , patient HIV may enrol . 7 . Nonpregnant nonnursing . Due unknown teratogenic potential Campath1H , pregnant nursing woman may enrol . Women men reproductive potential agree use effective mean birth control . 8 . Initial Required Laboratory Values : Creatinine &lt; 1.5 x upper limit institutional normal value Coomb 's Testing NEGATIVE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>